Sucampo Pharmaceuticals (SCMP) 6.77 $SCMP
Zogenix Shares Soar on Massachusetts Developments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:30PM CDT
Zogenix announced that the U.S. District Court in Massachusetts has entered an order preventing a ban on Zohydro ER on Constitutional grounds.
Dynavax Starts Phase III Study on Heplisav-B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 3:10PM CDT
Dynavax Technologies commenced a new phase III study (HBV-23) on its hepatitis B vaccine candidate, Heplisav-B
Alimera/pSivida Seek FDA Approval for Iluvien - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:45PM CDT
The FDA accepted Alimera Sciences' re-submitted NDA for Iluvien. PDUFA date for Iluvien is now set for Sep 26, 2014.
Pacira Prices Offering, Shares Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 11:00AM CDT
Shares of Pacira Pharmaceuticals soared 11.3% on the news of the pricing of the common stock at an offer price of $64.00 per share.
Tech Council of Maryland Names New Board Members
Business Wire - Thu Mar 27, 7:00AM CDT
The Tech Council of Maryland (TCM), Maryland's largest technology trade association for life science and technology, today announced that individuals from IBM, Sucampo Pharmaceuticals and the Universities at Shady Grove (USG) were named to the board of directors.
VLP Therapeutics Appoints Dr. Ryuji Ueno as Chair and Chief Medical Officer
PR Newswire - Tue Mar 25, 7:38AM CDT
VLP Therapeutics, Inc. ("VLP"
, a Rockville-based biotechnology company focusing on the research and development of next generation antibody agents and therapeutic as well as preventive vaccines based upon a novel and proprietary i-aVLP technology (which stands for "inserted alpha virus like particle", today announced that Ryuji Ueno, M.D., Ph.D., Ph.D., Co-Founder and former Chair, Chief Executive Officer and Chief Scientific Officer of Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) ("Sucampo" will join VLP as Chair and Chief Medical Officer, effective today.
Sucampo Co-Founder and Chairman Emeritus, Dr. Ryuji Ueno, to Receive Visionary Award From the Foundation Fighting Blindness
GlobeNewswire - Tue Mar 25, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the Foundation Fighting Blindness (Foundation), a national nonprofit driving sight-saving research, will honor Sucampo's Co-Founder and Chairman Emeritus, Ryuji Ueno, M.D., Ph.D., Ph.D., with the Foundation's Visionary Award, in recognition of Dr. Ueno's longstanding commitment to helping patients with eye diseases. The 12th Annual D.C. "For the Love of Sight" Visionary Awards Dinner will take place on Tuesday, April 1, at 6 p.m. Eastern, at the Ritz-Carlton - Downtown, Washington, D.C., to benefit research into preventions, treatments and cures for vision-robbing retinal diseases including macular degeneration, retinitis pigmentosa (RP), Usher syndrome and related conditions that affect more than 10 million Americans.
Sucampo's NDA Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 4:05PM CDT
Sucampo Pharma recently announced that its New Drug Application (NDA) for the liquid formulation of Amitiza will not be filed in the second half of 2014.
Sucampo and Takeda Announce Update on Liquid Formulation Program for AMITIZA(R) (lubiprostone)
GlobeNewswire - Fri Mar 14, 4:29PM CDT
Sucampo Pharma Americas, LLC, a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), and its development and commercialization partner's subsidiary Takeda Pharmaceuticals U.S.A., Inc. (Takeda) today announced that the New Drug Application (NDA) for the liquid formulation of AMITIZA (lubiprostone) will not be filed in the second half of 2014. In preliminary pre-NDA meeting comments, the FDA informed Sucampo that it would require additional data to characterize pharmacokinetics (PK) of the new formulation.
Regulatory Setback for Sucampo in the U.K. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 10:40AM CDT
Sucampo's type II variation of Amitiza refused approval for opioid- induced constipation (OIC) in the U.K.
Sucampo Receives Notice that Second Indication for AMITIZA for Opioid-Induced Constipation Is Not Approved by Medicines and Healthcare Products Regulatory Agency in U.K.
Thomson Reuters ONE - Wed Mar 12, 7:01PM CDT
Sucampo Will Evaluate All Options for Path Forward
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2014 ROTH Conference
GlobeNewswire - Wed Mar 05, 3:06PM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the 26 Annual ROTH Conference on Wednesday March 12, 2014 at 12:30 pm Pacific.
Sucampo and National Cherry Blossom Festival Announce Sucampo as Host and 'Step Into Spring' Program Sponsor for 2014
GlobeNewswire - Tue Mar 04, 9:00AM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP) and the National Cherry Blossom Festival (Festival) today announced their ongoing partnership to support the historic celebration of Japan's gift of cherry trees. Built on a passion for science and dedicated to supporting good health, Sucampo is co-sponsoring with the Festival this year's "Step Into Spring" fitness program. This program features free exercise and wellness classes over the course of the three weeks during the Festival, encouraging a healthy lifestyle for all participants.
Sucampo Gains On Better-Than-Expected Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 1:20PM CST
Shares of Sucampo Pharmaceuticals gained 11.9% following the release of fourth quarter results on Feb 26, 2014.
Why Sucampo Pharmaceuticals, Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 27, 11:34AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Sucampo Pharmaceuticals , a...
Sucampo Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
GlobeNewswire - Wed Feb 26, 3:09PM CST
Full Year Net Income Excluding Special Items of $9.4 Million, Up 94% over 2012 and Exceeds Guidance
UPS Honors Kansas Drivers for 25 Years of Safe Driving
Business Wire - Wed Feb 19, 9:00AM CST
UPS (NYSE:UPS) today announced 17 elite drivers from Kansas are among 1,519 newly inducted worldwide into the Circle of Honor, an honorary organization for UPS drivers who have achieved 25 or more years of accident-free driving.
Sucampo Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Results and Operating Highlights Teleconference and Webcast
GlobeNewswire - Wed Feb 12, 5:45AM CST
Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo", a global biopharmaceutical company, today announced that it will host a webcast and teleconference with senior management to discuss its financial results and operating highlights for the fourth quarter and full year ended December 31, 2013, on Wednesday, February 26, 2014, at 5:00 pm Eastern. The press release announcing the financial results and operating highlights is expected to be released after the close of the capital markets that day.
Sucampo Pharmaceuticals Inc elects Peter Greenleaf as CEO
M2 - Tue Feb 11, 7:11AM CST
Biopharmaceutical company Sucampo Pharmaceuticals Inc (NasdaqGM:SCMP) revealed on Monday the addition of Peter Greenleaf as its chief executive officer, as well as a member of its board of directors with effect from 3 March 2014.
Zogenix Shares Soar on Massachusetts Developments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:30PM CDT
Zogenix announced that the U.S. District Court in Massachusetts has entered an order preventing a ban on Zohydro ER on Constitutional grounds.
Dynavax Starts Phase III Study on Heplisav-B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 3:10PM CDT
Dynavax Technologies commenced a new phase III study (HBV-23) on its hepatitis B vaccine candidate, Heplisav-B
Alimera/pSivida Seek FDA Approval for Iluvien - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:45PM CDT
The FDA accepted Alimera Sciences' re-submitted NDA for Iluvien. PDUFA date for Iluvien is now set for Sep 26, 2014.
Pacira Prices Offering, Shares Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 11:00AM CDT
Shares of Pacira Pharmaceuticals soared 11.3% on the news of the pricing of the common stock at an offer price of $64.00 per share.
Tech Council of Maryland Names New Board Members
Business Wire - Thu Mar 27, 7:00AM CDT
The Tech Council of Maryland (TCM), Maryland's largest technology trade association for life science and technology, today announced that individuals from IBM, Sucampo Pharmaceuticals and the Universities at Shady Grove (USG) were named to the board of directors.
VLP Therapeutics Appoints Dr. Ryuji Ueno as Chair and Chief Medical Officer
PR Newswire - Tue Mar 25, 7:38AM CDT
VLP Therapeutics, Inc. ("VLP"
, a Rockville-based biotechnology company focusing on the research and development of next generation antibody agents and therapeutic as well as preventive vaccines based upon a novel and proprietary i-aVLP technology (which stands for "inserted alpha virus like particle", today announced that Ryuji Ueno, M.D., Ph.D., Ph.D., Co-Founder and former Chair, Chief Executive Officer and Chief Scientific Officer of Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) ("Sucampo" will join VLP as Chair and Chief Medical Officer, effective today. Sucampo Co-Founder and Chairman Emeritus, Dr. Ryuji Ueno, to Receive Visionary Award From the Foundation Fighting Blindness
GlobeNewswire - Tue Mar 25, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the Foundation Fighting Blindness (Foundation), a national nonprofit driving sight-saving research, will honor Sucampo's Co-Founder and Chairman Emeritus, Ryuji Ueno, M.D., Ph.D., Ph.D., with the Foundation's Visionary Award, in recognition of Dr. Ueno's longstanding commitment to helping patients with eye diseases. The 12th Annual D.C. "For the Love of Sight" Visionary Awards Dinner will take place on Tuesday, April 1, at 6 p.m. Eastern, at the Ritz-Carlton - Downtown, Washington, D.C., to benefit research into preventions, treatments and cures for vision-robbing retinal diseases including macular degeneration, retinitis pigmentosa (RP), Usher syndrome and related conditions that affect more than 10 million Americans.
Sucampo's NDA Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 4:05PM CDT
Sucampo Pharma recently announced that its New Drug Application (NDA) for the liquid formulation of Amitiza will not be filed in the second half of 2014.
Sucampo and Takeda Announce Update on Liquid Formulation Program for AMITIZA(R) (lubiprostone)
GlobeNewswire - Fri Mar 14, 4:29PM CDT
Sucampo Pharma Americas, LLC, a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), and its development and commercialization partner's subsidiary Takeda Pharmaceuticals U.S.A., Inc. (Takeda) today announced that the New Drug Application (NDA) for the liquid formulation of AMITIZA (lubiprostone) will not be filed in the second half of 2014. In preliminary pre-NDA meeting comments, the FDA informed Sucampo that it would require additional data to characterize pharmacokinetics (PK) of the new formulation.
Regulatory Setback for Sucampo in the U.K. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 10:40AM CDT
Sucampo's type II variation of Amitiza refused approval for opioid- induced constipation (OIC) in the U.K.
Sucampo Receives Notice that Second Indication for AMITIZA for Opioid-Induced Constipation Is Not Approved by Medicines and Healthcare Products Regulatory Agency in U.K.
Thomson Reuters ONE - Wed Mar 12, 7:01PM CDT
Sucampo Will Evaluate All Options for Path Forward
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2014 ROTH Conference
GlobeNewswire - Wed Mar 05, 3:06PM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the 26 Annual ROTH Conference on Wednesday March 12, 2014 at 12:30 pm Pacific.
Sucampo and National Cherry Blossom Festival Announce Sucampo as Host and 'Step Into Spring' Program Sponsor for 2014
GlobeNewswire - Tue Mar 04, 9:00AM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP) and the National Cherry Blossom Festival (Festival) today announced their ongoing partnership to support the historic celebration of Japan's gift of cherry trees. Built on a passion for science and dedicated to supporting good health, Sucampo is co-sponsoring with the Festival this year's "Step Into Spring" fitness program. This program features free exercise and wellness classes over the course of the three weeks during the Festival, encouraging a healthy lifestyle for all participants.
Sucampo Gains On Better-Than-Expected Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 1:20PM CST
Shares of Sucampo Pharmaceuticals gained 11.9% following the release of fourth quarter results on Feb 26, 2014.
Why Sucampo Pharmaceuticals, Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 27, 11:34AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Sucampo Pharmaceuticals , a...
Sucampo Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
GlobeNewswire - Wed Feb 26, 3:09PM CST
Full Year Net Income Excluding Special Items of $9.4 Million, Up 94% over 2012 and Exceeds Guidance
UPS Honors Kansas Drivers for 25 Years of Safe Driving
Business Wire - Wed Feb 19, 9:00AM CST
UPS (NYSE:UPS) today announced 17 elite drivers from Kansas are among 1,519 newly inducted worldwide into the Circle of Honor, an honorary organization for UPS drivers who have achieved 25 or more years of accident-free driving.
Sucampo Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Results and Operating Highlights Teleconference and Webcast
GlobeNewswire - Wed Feb 12, 5:45AM CST
Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"
, a global biopharmaceutical company, today announced that it will host a webcast and teleconference with senior management to discuss its financial results and operating highlights for the fourth quarter and full year ended December 31, 2013, on Wednesday, February 26, 2014, at 5:00 pm Eastern. The press release announcing the financial results and operating highlights is expected to be released after the close of the capital markets that day. Sucampo Pharmaceuticals Inc elects Peter Greenleaf as CEO
M2 - Tue Feb 11, 7:11AM CST
Biopharmaceutical company Sucampo Pharmaceuticals Inc (NasdaqGM:SCMP) revealed on Monday the addition of Peter Greenleaf as its chief executive officer, as well as a member of its board of directors with effect from 3 March 2014.
